
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral liquid containing rifampin, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing rifampin are listed in capsule and injection forms.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Rifampin is an antibiotic made as capsules and as an injection that a pharmacy may compound into an oral liquid when a prescriber orders it.
Rifampin, also called rifampicin, is an antibiotic in the rifamycin family. It stops susceptible bacteria from making RNA by blocking their RNA polymerase; it does not block the human form of that enzyme. Rifampin is manufactured as oral capsules and in an intravenous form. Rifampin capsules are FDA-approved, as part of combination therapy, for all forms of tuberculosis, and for eliminating meningococci from the nose and throat of people who carry Neisseria meningitidis without symptoms; they are not approved for treating meningococcal infection itself. The manufactured capsule label describes how a pharmacy can prepare an oral suspension from capsule contents for patients who have trouble swallowing capsules or need lower doses. Compounded preparations are not FDA-approved and require a prescription.
Rifampin labels carry no boxed warning. It can cause liver injury, from mild enzyme changes to fatal liver failure; tell your prescriber about nausea, loss of appetite, dark urine or yellow skin or eyes. Do not use it if you are allergic to rifampin or other rifamycins. Rifampin speeds the breakdown of many medicines and is contraindicated with several HIV drugs, praziquantel and lurasidone; it can make hormonal birth control fail, so use a non-hormonal method. It turns urine, sweat, tears and other body fluids yellow, orange, red or brown and can permanently stain soft contact lenses. Given late in pregnancy, it can cause bleeding in the mother and newborn. LactMed says milk levels are low and breastfeeding should not be discouraged, though milk may be discolored. Get help right away for rash, swelling, trouble breathing or bloody diarrhea; for other side effects, talk to your prescriber or pharmacist.
Rifampin inhibits DNA-dependent RNA polymerase in susceptible organisms, including Mycobacterium tuberculosis, without inhibiting the mammalian enzyme. It is readily absorbed orally; food reduces absorption by about 30%. It is about 80% protein bound, distributes widely including into cerebrospinal fluid, is eliminated in bile with enterohepatic circulation and progressive deacetylation, and has a serum half-life of a few hours that shortens with repeated dosing. Labeled indications (rifampin capsules, Lupin): all forms of tuberculosis in combination regimens, and asymptomatic Neisseria meningitidis carriers. The rifampin capsule label gives a procedure for compounding an oral suspension from capsule contents, with stability data, for patients who have difficulty swallowing capsules or need lower doses. StatPearls notes off-label use in leprosy and selected severe gram-positive infections; these are not FDA-approved indications. Dosing is per prescriber. Rifampin induces CYP1A2, 2B6, 2C8, 2C9, 2C19 and 3A4, UGTs and P-glycoprotein; review all concomitant drugs, and monitor prothrombin time with oral anticoagulants. In adults treated for tuberculosis, obtain baseline hepatic enzymes, bilirubin, serum creatinine, complete blood count and platelets, and monitor liver function closely in hepatic impairment. Use caution in diabetes and porphyria. Rifampin can cause false-positive opiate urine screens and interferes with microbiological folate and vitamin B12 assays.
Shake the bottle if your label says to. Measure each dose with the oral syringe or dosing cup the pharmacy gave you, never a kitchen spoon. Give the liquid slowly into the mouth. Rinse the syringe with water after each use. Call the pharmacy if you are unsure how to measure.
Storage depends on the vehicle. Water-based liquids with a preservative usually carry a USP <795> beyond-use date of up to 35 days; without a preservative they are kept refrigerated for up to 14 days. Oil-based (nonaqueous) oral liquids may carry up to 90 days. Your label states whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally